Pengyu Jing | Lung Cancer Progression | Research Excellence Award

Published on by Cell Biologist

Mr. Pengyu Jing | Lung Cancer Progression | Research Excellence Award

The Second Affiliated Hospital of Air Force Medical University | China

A thoracic surgery specialist with extensive experience in minimally invasive treatment of lung cancer, mediastinal tumors, and pulmonary diseases, focusing on multidisciplinary clinical approaches including surgery, biopsy, and ablation. Research interests center on tumor microenvironment, epigenetics, antitumor drug development, and pulmonary fibrosis modeling. Has led multiple national and provincial research projects and contributed to international clinical trials. Authored over 20 SCI-indexed publications with significant impact in oncology and cell biology, particularly on PRMT5-related mechanisms in lung cancer progression and therapy resistance. Actively involved in academic editorial work, peer review, and professional scientific committees, contributing to advancements in thoracic oncology research and clinical practice.

Citation Metrics (Scopus)

600
400
200
100
50
20
0

Citations
581

Documents
27

h-index
12

Citations

Documents

h-index

Featured Publications

Mr. Rahul Das Gupta | Cancer Cell Biology | Editorial Board Member

Published on by Cell Biologist

Mr. Rahul Das Gupta | Cancer Cell Biology | Editorial Board Member

Maulana Abul Kalam Azad University of Technology | India

Rahul Das Gupta is a biotechnology researcher with expertise in cancer biology, nanomedicine, and computational drug discovery. His work focuses on exosome-based liquid biopsy for early brain cancer detection and in-silico screening of plant-derived anticancer compounds targeting oncogenic pathways. He has synthesized bio-metallic nanoparticles using medicinal plant extracts and evaluated their antimicrobial and cytotoxic potential through experimental and computational approaches, including EGFR and VEGFR interaction studies. Skilled in molecular biology, cell culture, bioinformatics, and advanced characterization techniques, he integrates laboratory research with computational analysis. His publication in Biochemical and Biophysical Research Communications highlights his contributions to translational cancer research.

Citation Metrics (Google Scholar)

2
1.5
1
0.5
0

Citations
2

h-index
1

i10-index
0

Citations

h-index

i10-index

Featured Publications

Ji Cao | Macrophage Biology | Research Excellence Award

Published on by Cell Biologist

Prof. Ji Cao | Macrophage Biology | Research Excellence Award

Zhejiang University | China

Ji Cao, Ph.D., is a leading scholar in tumor pharmacology and anticancer drug discovery, internationally recognized as a World’s Top 2% Scientist (Stanford ranking, 2023) and a National Young Top Talent of China. His research integrates tumor pharmacology, chemical biology, and artificial intelligence–driven drug design, with major contributions to targeted protein degradation (PROTACs), ferroptosis regulation, MYC oncoprotein inhibition, and cancer immunotherapy. He has published over 59 peer-reviewed articles in high-impact journals such as Cell Metabolism, Nature Communications, PNAS, and Science Advances, including multiple ESI highly cited papers, accumulating more than 4,000 citations with an h-index of 36. His work has translated into innovation through 18 Chinese patents and one international patent. He has led nationally and provincially funded projects exceeding ¥14 million and has received prestigious science and technology awards for outstanding contributions to biomedical research and translational pharmacology.

Citation Metrics (Scopus)

6000
4000
2000
200
100
50
0

Citations
5,725

Documents
149

h-index
44

Citations

Documents

h-index

Featured Publication

Ilaria Cossu | Immunology Cellular Interactions | Research Excellence Award

Published on by Cell Biologist

Ms. Ilaria Cossu | Immunology Cellular Interactions | Research Excellence Award

University of Sassari | Italy

Ilaria Cossu is a motivated PhD candidate in Life Sciences and Biotechnologies with a specialization in Microbiology and Immunology. Their work focuses on understanding the role of human endogenous retroviruses (HERVs) in cancer, integrating molecular biology, immunology, and virology approaches to explore how retroviral elements may influence tumorigenesis. Their doctoral project involves conducting indirect ELISA assays, maintaining and analyzing cell cultures, processing blood samples, performing RNA extraction and reverse transcription, and carrying out quantitative PCR for gene expression profiling. The researcher is actively engaged in experimental design, data analysis, scientific writing, and collaborative research activities at both national and international levels.

Prior academic training includes Master’s and Bachelor’s degrees in Biology, each completed with top distinction, and research internships in microbiology, virology, and biochemistry laboratories. These experiences provided hands-on expertise in electrophoretic methods such as cellulose acetate electrophoresis, C-PAGE, fluorescent 2-aminoacridone probe (FACE) analysis, and SDS-PAGE, contributing to a solid foundation in protein and nucleic acid characterization. Their current research aims to advance understanding of retroviral contributions to cancer biology and supports the development of innovative molecular approaches for disease investigation and potential therapeutic insights.

Profile: Scopus

Featured Publications:

Cossu, I., Ruberto, S., Filippi, E., Simula, E. R., Noli, M., Mottula, A., & others. (2025). HERV-K envelope induces a humoral response in Non-Hodgkin lymphoma patients. Current Microbiology, 82(12), 574.

Jasemi, S., Molicotti, P., Fais, M., Cossu, I., Simula, E. R., Sechi, L. A., & others. (2025). Biological mechanisms of enterotoxigenic Bacteroides fragilis toxin: Linking inflammation, colorectal cancer, and clinical implications. Toxins, 17(6), 305.

Simula, E. R., Jasemi, S., Cossu, D., Fais, M., Cossu, I., Chessa, V., & others. (2025). Human endogenous retroviruses as novel therapeutic targets in neurodegenerative disorders. Vaccines, 13(4), 415. h

Ruberto, S., Santovito, A., Caviglia, G. P., Noli, M., Cossu, D., Ribaldone, D. G., & others. (2025). Mycobacterium avium subsp. paratuberculosis and human endogenous retrovirus in Italian patients with inflammatory bowel disease and irritable bowel syndrome. Immunology.

Varsha Rathore | Cancer Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Varsha Rathore | Cancer Biology | Best Researcher Award

Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 100233 | Taiwan

Dr. Varsha Rathore’s research focuses on elucidating the molecular mechanisms underlying cancer cell migration, invasion, and survival, with a particular emphasis on the role of CASK (Calcium/Calmodulin-dependent Serine Protein Kinase) in prostate cancer progression. Her doctoral work explores how CASK promotes tumor cell motility and invasiveness independent of TGF-β signaling, contributing to a deeper understanding of tumor metastasis. Additionally, she investigates the involvement of NLRX1 in regulating proliferation, invasion, and survival pathways in prostate cancer cells, offering insights into novel therapeutic targets for cancer treatment. Her expertise spans cell culture, molecular biology, and biochemical assays, including protein expression, purification, ubiquitination, kinase, and PARylation assays, as well as metabolic analysis using Seahorse technology. She has presented her findings at international conferences, including the 19th World Congress of Basic and Clinical Pharmacology and the 38th Joint Academic Conference on Biomedicine. Through her research, Dr. Rathore contributes significantly to the field of molecular oncology and pharmacology, advancing knowledge on how signaling proteins orchestrate cancer progression and identifying potential molecular targets for therapeutic intervention.

Profile: Orcid

Featured Publications:

Rathore, V., Cheng, C.-Y., Lin, C.-Y., Chang, C.-R., & Lin, W.-W. (2025). CASK promotes prostate cancer progression via kinase-dependent activation of AKT. International Journal of Biological Macromolecules, 311(Pt 2), 143965.

Rathore, V., & Lin, W.-W. (2025). Decoding SIGLEC12 in bladder cancer: In silico profiling of expression, tumor–immune interactions, and prognostic impact. Medicina, 61(11), 1894.

Mishra, M., Rathore, V., Sahu, S., & Sahoo, H. (2019). The contribution of nanostructures towards the wing patterning of yellow Catopsilia pomona: How it differs from the lime. Microscopy, 68(4), 289–300.

Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Published on by Cell Biologist

Dr. Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Edinburgh of University | United Kingdom

Dr. Amirhosein Kefayat is a clinical research fellow at the Institute of Genetics and Cancer, University of Edinburgh, with over fourteen years of dedicated experience in translational and clinical cancer research. Since his early days in medical school, he has pursued a strong passion for advancing oncology through both laboratory and clinical investigations, contributing to more than 60 peer-reviewed publications that have collectively garnered over 2,300 citations, with a Google Scholar H-index of 28. His research spans biomaterials, nanomedicine, wound healing, immunoinformatics, and cancer vaccine design, with several of his papers ranking among the top 1% most-cited in their respective years of publication. Notably, his work on innovative wound dressings, cancer-testis antigen vaccines, and gold nanoclusters for radiosensitization has made significant impacts within the fields of biomaterials and cancer therapeutics. Alongside his research, he is currently advancing his academic qualifications through a Postgraduate Certificate of Academic Practice at the University of Edinburgh and Associate Principal Investigator Training with NIHR. Recognized among the top 0.5% of cancer researchers worldwide, his career reflects a consistent commitment to bridging basic science and clinical application to improve patient care.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Eskandarinia, A., Kefayat, A., Agheb, M., Rafienia, M., Amini Baghbadorani, M., & Navid, S. (2020). A novel bilayer wound dressing composed of a dense polyurethane/propolis membrane and a biodegradable polycaprolactone/gelatin nanofibrous scaffold. Scientific Reports, 10(1), 3063.

Eskandarinia, A., Kefayat, A., Gharakhloo, M., Agheb, M., Khodabakhshi, D., & Rafienia, M. (2020). A propolis enriched polyurethane-hyaluronic acid nanofibrous wound dressing with remarkable antibacterial and wound healing activities. International Journal of Biological Macromolecules, 149, 467–476.

Safavi, A., Kefayat, A., Mahdevar, E., Abiri, A., & Ghahremani, F. (2020). Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine, 38(48), 7612–7628.

Khodabakhshi, D., Eskandarinia, A., Kefayat, A., Rafienia, M., Navid, S., & Karbasi, S. (2019). In vitro and in vivo performance of a propolis-coated polyurethane wound dressing with high porosity and antibacterial efficacy. Colloids and Surfaces B: Biointerfaces, 178, 177–184.

Eskandarinia, A., Kefayat, A., Rafienia, M., Agheb, M., Navid, S., & Ebrahimpour, K. (2019). Cornstarch-based wound dressing incorporated with hyaluronic acid and propolis: In vitro and in vivo studies. Carbohydrate Polymers, 216, 25–35.

Farhad Ghorbani | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Farhad Ghorbani | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Farhad Ghorbani | Shiraz University of Medical Sciences ,Shiraz,Iran | Iran

Dr. Farhad Ghorbani is an esteemed Assistant Professor of Oral and Maxillofacial Surgery at Shiraz University of Medical Sciences, Iran. With over two decades of clinical and academic experience, he has significantly contributed to the fields of oral pathology, trauma, and surgical interventions. A graduate of Kerman University of Medical Sciences, Dr. Ghorbani later specialized further at Shiraz University. His dedication to advancing clinical knowledge is reflected in over a dozen high-impact peer-reviewed publications, focusing on craniofacial abnormalities, surgical outcomes, and rare oral diseases. He is an active researcher with a Scopus Author ID and ORCID, consistently contributing to scientific journals like BMC Oral Health, Scientific Reports, and Maxillofacial Plastic and Reconstructive Surgery. His multidisciplinary collaborations have led to enhanced diagnostic techniques and patient outcomes. Dr. Ghorbani is recognized for both his innovative research and his commitment to medical education.

Publication Profile: 

Orcid

Google Scholar

Education:

Dr. Ghorbani began his medical journey at Kerman University of Medical Sciences, earning his professional doctorate in dentistry (1992–1998). Following years of clinical practice, he advanced his academic and surgical expertise by joining Shiraz University of Medical Sciences in 2013, where he underwent specialized training in Oral and Maxillofacial Surgery and served as an Assistant Professor during his educational tenure (2013–2018). His academic training focused on maxillofacial pathology, surgical techniques, and interdisciplinary diagnostics. The combination of strong foundational medical education and advanced surgical specialization has equipped him with both the theoretical depth and clinical acumen to lead impactful research. His training underlines a commitment to academic excellence and lifelong learning, which is further reflected in his scholarly contributions. Dr. Ghorbani’s educational background bridges foundational dental sciences with advanced surgical innovation.

Experience:

Since December 2018, Dr. Farhad Ghorbani has held the position of Assistant Professor of Oral and Maxillofacial Surgery at Shiraz University of Medical Sciences, Iran. His career blends clinical practice, research, and teaching. Over the years, he has led numerous studies exploring craniofacial morphology, surgical outcomes, dental trauma, and maxillofacial pathologies. He mentors postgraduate students and collaborates with interdisciplinary teams, enhancing diagnostic accuracy and surgical care. His work in both rural and urban settings has exposed him to a wide spectrum of maxillofacial cases, enriching his clinical insights. He actively contributes to improving surgical protocols and patient care standards. Dr. Ghorbani’s experience also includes academic publishing, peer reviews, and participation in scientific forums. He is recognized for his analytical approach and evidence-based practice. His long-standing affiliation with reputed institutions and research groups underscores his strong leadership in oral surgery and academic scholarship.

Research Focus:

Dr. Ghorbani’s primary research interests lie in oral pathology, craniofacial surgery, dentoalveolar trauma, and radiological diagnostics. His work often combines clinical case reports with retrospective analysis, offering insights into rare presentations such as parathyroid carcinoma-linked jaw tumors, and developmental anomalies like concha bullosa. A hallmark of his research is his ability to identify atypical symptoms and connect them with broader systemic conditions, ensuring early diagnosis and management. He has conducted fractal analysis studies to evaluate bone quality, and he explores patient-centered outcomes, such as satisfaction post-rhinoplasty and the psychological impacts of facial surgery. Additionally, his research evaluates the intersection of dental surgery with systemic health—evident in studies related to auditory changes post-orthognathic surgery or the implications of COVID-19 on dental care. Through evidence-based methods and innovative case analyses, Dr. Ghorbani has positioned himself as a thought leader in interdisciplinary oral and maxillofacial research.

Publications Top Notes:

  1. Brown tumors of both jaws as the initial manifestation of parathyroid carcinoma (BMC Oral Health, 2025)

  2. Distribution and laterality of concha bullosa across cranial skeletal types (Maxillofacial Plastic Surg, 2025)

  3. Calcifying Odontogenic Cyst in Posterior Maxilla: A Case Report (Journal of Dentistry Shiraz, 2025)

  4. Central giant cell granuloma mimicking fibro-osseous lesion and hemangioma (J Med Case Reports, 2024)

  5. Fractal CT analysis of mandibular condyles in class III malocclusion (Scientific Reports, 2023)

  6. Patient dissatisfaction following rhinoplasty: A 10-year Iranian study (Maxillofacial Plastic Surg, 2023)

  7. Correlation between impacted third molar and blood group (Int J of Dentistry, 2021)

  8. Effects of orthognathic surgery on auditory function (Maxillofacial Plastic Surg, 2021)

  9. Evaluation of alveolar fractures in trauma patients in Iran (BMC Oral Health, 2021)

  10. Anxiety in patients undergoing mandibular third molar extraction (J Oral Research & Review, 2020)

Conclusion:

In summary, Dr. Farhad Ghorbani embodies the qualities of a deeply committed, analytically skilled, and academically active oral and maxillofacial surgeon. His research is directly informed by his clinical experience, allowing him to bridge theory and practice effectively. His contributions have enriched the literature on oral pathology, surgical complications, facial aesthetics, and patient psychology following treatment interventions. While there are opportunities to expand the scope and scale of his work through more robust methodologies and international collaboration, his existing portfolio already reflects a high standard of academic and clinical integration. Given his track record, ongoing research productivity, and evident commitment to innovation and education, Dr. Ghorbani is a strong and deserving candidate for the Best Researcher Award. With continued growth in research leadership and expanded global outreach, he is poised to make an even greater impact in the years ahead.

Fani Pantouli | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Dr. Fani Pantouli | Immunology Cellular Interactions | Best Researcher Award

Dr. Fani Pantouli, Cleveland Clinic Florida Research and Innovation Center, United States

Dr. Fani Pantouli is a passionate and results-driven research scientist with deep expertise in neuroscience, pharmacology, immunology, and oncology. A USA permanent resident, she currently serves as a Postdoctoral Fellow at the Cleveland Clinic Florida Research and Innovation Center. Her work bridges cutting-edge vaccine development and cancer therapeutics, contributing significantly to preclinical and translational research. Dr. Pantouli’s scientific approach blends in vivo and in vitro techniques to uncover therapeutic pathways, particularly in head and neck cancer and viral immunology. Her interdisciplinary knowledge is reflected in a growing portfolio of peer-reviewed publications addressing pressing biomedical challenges, from COVID-19 immunity to neuropsychiatric disorders. She is known for her innovative methodologies, collaborative mindset, and unwavering dedication to advancing human health. Dr. Pantouli’s work is making a meaningful impact on personalized medicine and translational therapeutics, positioning her as a rising leader in biomedical research.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Multidisciplinary Expertise
    Dr. Pantouli integrates neuroscience, immunology, pharmacology, and oncology into her research, making her contributions uniquely cross-disciplinary and impactful.

  2. High-Impact Research in Vaccine Development
    Her postdoctoral work on COVID-19 and respiratory viruses, particularly her development of T-cell profiling and viral neutralization assays, directly informs global efforts in personalized vaccine design.

  3. Innovative Cancer Models
    She developed a novel in vivo murine model for head and neck squamous cell carcinoma, advancing drug screening for p53-related targets. This is vital in understanding and treating cancers with p53 mutations.

  4. Robust Publication Record
    Dr. Pantouli has authored or co-authored multiple peer-reviewed articles in reputable journals (e.g., Vaccines, Neuropsychopharmacology), with several under review in top-tier outlets like Science and Journal of Biological Psychiatry.

  5. Focus on Health Equity
    Her research into ethnic differences in immune response underscores a strong commitment to inclusive and equitable healthcare.

  6. Experience in Preclinical & Translational Research
    Her hands-on experience building disease models and testing therapeutic strategies bridges basic science and clinical application—core to translational medicine.

⚠️ Areas for Improvement:

  1. Independent Research Leadership
    While she has made significant contributions as a postdoctoral fellow, moving toward independent investigator roles (e.g., PI on grants) would strengthen her candidacy.

  2. Visibility and Recognition
    Increased presence in international symposia, keynote talks, or award recognitions would help boost her visibility within the scientific community.

  3. Mentorship and Community Involvement
    Involvement in mentoring junior researchers or leading educational outreach initiatives could further showcase her leadership potential.

🎓 Education:

Dr. Pantouli holds a Ph.D. in Neuropharmacology from the University of Surrey and St. George’s University of London, awarded between 2014 and 2017. Her doctoral studies explored neural mechanisms underpinning pharmacological and behavioral outcomes, laying a solid foundation for her current work in translational medicine. Prior to her Ph.D., she completed an MSc in Molecular Neuroscience from the University of Bristol in 2011, where she specialized in neurodevelopmental and degenerative disorders. Her undergraduate studies were completed at the University of Bedfordshire in 2010, where she earned a BSc (Hons) in Biomedical Science. Dr. Pantouli’s academic trajectory reflects a commitment to interdisciplinary learning and a focus on brain and immune system interactions. Her education combines rigorous training in molecular biology, pharmacology, and neuroscience, empowering her to address complex biomedical questions with a systems-level perspective.

🧪 Experience:

Dr. Pantouli is currently a Postdoctoral Fellow in Vaccine Development Research at the Cleveland Clinic Florida Research and Innovation Center (June 2023 – Present), where she investigates T cell immune responses and develops viral neutralization assays for respiratory viruses including SARS-CoV-2. Previously, she was a Postdoctoral Fellow in the Cancer Research Lab at the same institute (January 2022 – June 2023), where she created innovative murine models of head and neck cancer to evaluate therapeutic efficacy targeting mutant p53. Her research integrates advanced in vivo systems and immune profiling to enhance drug discovery and vaccine evaluation. With a decade-long track record across academia and clinical research centers, Dr. Pantouli has developed robust platforms for translational research, immunotherapeutics, and precision medicine. Her skills span experimental design, animal modeling, immunoassays, and bioanalysis, equipping her to tackle critical gaps in infectious disease and oncology treatment strategies.

🔬 Research Focus:

Dr. Pantouli’s research is centered on translational medicine, focusing on vaccine development, immunotherapy, and molecular pharmacology. Her current projects address immune modulation in viral infections, especially COVID-19, and the development of preclinical assays for vaccine and drug evaluation. She also leads research in oncology, particularly targeting p53 mutations in head and neck squamous cell carcinoma using in vivo models. Her earlier academic work examined the neural and behavioral effects of neuropeptides and receptor modulators in models of autism and Fragile X Syndrome, showing a consistent interest in neuroimmune interactions. She employs a multidisciplinary approach—blending pharmacological, molecular, and immunological tools—to explore how targeted therapies can be optimized for diverse populations. Her work is vital for advancing personalized medicine, especially for aging populations and ethnically diverse cohorts, where vaccine efficacy and immune response can differ significantly.

📚 Publications Top Notes:

  • 🧫 Ethnic differences in COVID-19 T cell immunity responses across variants from Wuhan to Omicron – Accepted in Vaccines

  • 🧠 Evaluation of SR-17018 and oxycodone in the conditioned place preference paradigm using peanut butter chip vehicle – In preparation, Neuropharmacology

  • 🧬 Generation of antigen-specific paired heavy-light chain antibody sequences using large language models – Submitted to Science

  • 💉 COVID-19 Vaccination Enhances the Immunogenicity of Seasonal Influenza Vaccination in the Elderly – Vaccines (2025)

  • 🧩 Tilted striatofugal balance and mGluR4 modulation in the Fmr1 mouse model of Fragile X Syndrome – Under review, Journal of Biological Psychiatry

  • 👃 Acute, chronic and conditioned effects of intranasal oxytocin in mu opioid receptor knockout mice: social context matters – Neuropsychopharmacology (2024)

🧾 Conclusion:

Dr. Fani Pantouli is a highly promising and impactful scientist whose research spans some of the most critical health challenges of our time—infectious diseases, cancer, and neurodevelopmental disorders. Her technical expertise, innovative model development, and deep understanding of immune and neural systems make her an excellent nominee for the Best Researcher Award.

Balbino Alarcón | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Balbino Alarcón | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Balbino Alarcón , Consejo Superior de Investigaciones Científicas , Spain

Balbino Alarcón is a leading Spanish immunologist renowned for his contributions to T cell biology and immune signaling. Currently serving as Profesor de Investigación at the Consejo Superior de Investigaciones Científicas (CSIC), he has been affiliated with the Centro de Biología Molecular Severo Ochoa since 2002. His research has played a pivotal role in uncovering mechanisms of T cell receptor (TCR) signaling and immune system regulation. Dr. Alarcón holds a PhD in Biology from the Universidad Autónoma de Madrid, where he began shaping his scientific journey in the early 1980s. Over the decades, he has authored numerous impactful publications, many in top-tier journals, and holds several patents licensed to biotech companies. His work bridges fundamental immunology with translational applications in autoimmunity and cancer. With a keen focus on molecular signaling, his research continues to influence both basic science and therapeutic innovation in immunology.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Outstanding Research Contributions:
    Dr. Alarcón has made seminal contributions to immunology, especially in T cell receptor (TCR) signaling, immune synapse formation, and immune cell communication. His work has appeared in top-tier journals like Cell, Immunity, Nature Communications, and Journal of Experimental Medicine.

  2. Impactful Publications & Citations:
    His research includes several highly cited papers (e.g., >500 citations), underlining the influence of his work on the broader scientific community.

  3. Translational Achievements:
    He holds multiple patents on immunomodulatory molecules (e.g., AX-024), which were licensed to biotech company Artax Biopharma, bridging basic science and clinical application.

  4. SARS-CoV-2 Research Leadership:
    He actively contributed to COVID-19 immunity research, developing flow cytometry-based antibody detection techniques and tracking longitudinal immune responses to infection and vaccination.

  5. Longevity and Commitment:
    Over 40 years of consistent research activity, with continuous affiliation to one of Spain’s most prestigious scientific institutions, CSIC.

  6. International Collaboration:
    He co-authored papers with leaders in immunology, showing global recognition and collaboration.

🛠️ Areas for Improvement:

  • Public Engagement & Visibility:
    Despite scientific acclaim, more visibility in public science communication, conference keynote roles, or leadership in global immunology consortia would further support his candidacy.

  • Mentorship Highlighting:
    While his academic stature suggests mentorship, documentation or awards for training young scientists could enhance his profile for broader awards recognizing holistic impact.

  • Innovation Metrics:
    Increased emphasis on clinical translation or successful product development from his patents could strengthen claims to innovation-driven recognitions.

🎓 Education:

Dr. Balbino Alarcón completed his undergraduate degree (Licenciado en Biología) in 1982 and his PhD in Biology with a specialization in Biochemistry in 1985, both from the Universidad Autónoma de Madrid, Spain. During his academic formation, he developed a deep interest in immunological signaling, particularly in how T cells communicate with their environment. His early education laid the foundation for a distinguished research career that has spanned more than three decades. His doctoral studies were focused on cellular and molecular immunology, equipping him with the tools to explore intricate signaling pathways. This robust educational background positioned him for leadership roles in immunological research, both nationally and internationally. Through rigorous academic training and continuous research contributions, Dr. Alarcón has become a key figure in advancing our understanding of T cell function and immune regulation.

👨‍🔬 Experience:

Dr. Balbino Alarcón has over 40 years of experience in immunological research, with a primary focus on T cell receptor (TCR) signaling and lymphocyte activation. Since July 27, 2002, he has held the position of Profesor de Investigación at the Consejo Superior de Investigaciones Científicas (CSIC), working at the Centro de Biología Molecular Severo Ochoa in Madrid, Spain. His academic and research career began with groundbreaking studies in T cell immunobiology, leading to discoveries such as the role of conformational changes in TCR activation. Dr. Alarcón has also been deeply involved in translational research, co-developing immunomodulatory drugs and securing patents that were licensed to Artax Biopharma. He regularly collaborates with leading immunologists and institutions worldwide, contributing to high-impact publications and international scientific reviews. His expertise and sustained contributions have made him a mentor and authority in molecular immunology and T cell biology.

🏅 Awards and Honors:

Dr. Balbino Alarcón’s distinguished career is highlighted by several prestigious awards and intellectual property recognitions. He co-developed two patented immunosuppressive strategies based on TCR signaling inhibition: one disrupting the TCR-Nck interaction and another involving chromene derivatives. Both patents were licensed to Artax Biopharma, showcasing the real-world therapeutic relevance of his research. He has authored highly cited publications, including foundational work published in Cell, Immunity, and Annual Review of Immunology, with citations in the hundreds. These contributions have not only advanced the field of immunology but also positioned Dr. Alarcón as a thought leader in immune signal transduction. He has been recognized nationally and internationally for his scientific achievements, serving as an editorial contributor and co-author of influential immunological reviews. His work continues to shape both academic and pharmaceutical research, making him a strong candidate for Best Researcher Awards.

🔬 Research Focus:

Dr. Alarcón’s research centers on the molecular mechanisms governing T cell receptor (TCR) activation and signal transduction. His work dissects how T cells recognize antigens and how intracellular signaling cascades translate these interactions into immune responses. A significant aspect of his research has involved understanding the conformational dynamics of the TCR/CD3 complex and how this affects T cell sensitivity and activation thresholds. He also explores the role of RRas2 in T and B cell function, including its relevance in lymphomagenesis and autoimmunity. Recently, he has contributed to understanding immune responses to SARS-CoV-2 and methods to detect neutralizing antibodies. His interdisciplinary approach integrates cell biology, molecular immunology, and translational research, linking fundamental science to clinical applications such as vaccine development and immunotherapy. By targeting TCR-associated pathways, Dr. Alarcón’s research opens new avenues in the treatment of immune-related diseases and cancer.

📚 Publications Top Notes:

  1. 🧫 RRas2 is required for germinal center formation to aid B cells during energetically demanding processes (Sci Signal, 2018)

  2. 🧪 A window of opportunity for cooperativity in the T Cell Receptor (Nat Commun, 2018)

  3. 🧬 Antigen phagocytosis by B cells is required for a potent humoral response (EMBO Rep, 2018)

  4. ⚙️ RRAS2 shapes the TCR repertoire by setting the threshold for negative selection (J Exp Med, 2019)

  5. 💊 Small molecule AX-024 targets T cell receptor signaling by disrupting CD3ε-Nck interaction (J Biol Chem, 2020)

  6. 🧪 Flow cytometry multiplexed method for the detection of Neutralizing human antibodies to SARS-CoV-2 (EMBO Mol Med, 2021)

  7. 🧬 Antigen presentation between T-cells drives Th17 polarization under limiting antigen (Cell Rep, 2021)

  8. 🧫 Detection of sustained humoral immune response (IgG + IgA) in SARS-CoV-2 infection (Sci Rep, 2021)

  9. 🧠 SFRP1 modulates astrocyte-to-microglia crosstalk in neuroinflammation (EMBO Rep, 2021)

  10. 💉 Longitudinal dynamics of SARS-CoV-2-specific immunity after infection or vaccination (PLoS Pathog, 2021)

🧾 Conclusion:

Dr. Balbino Alarcón is a highly deserving candidate for the Best Researcher Award. His pioneering studies in T cell signaling, impactful biomedical patents, and active role in immune response to infectious diseases demonstrate excellence in both basic and translational immunology. With decades of productive research, interdisciplinary collaboration, and consistent scientific leadership, he embodies the qualities celebrated by such an award.

Miroslaw Markiewicz | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Miroslaw Markiewicz | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Miroslaw Markiewicz , Faculty of Medicine, Collegium Medicum, University of Rzeszow , Poland

Mirosław Markiewicz is a distinguished medical professional specializing in hematology, internal medicine, and bone marrow transplantation. With over three decades of experience in the medical field, he holds the title of Professor and has made significant contributions to the advancement of hematopoietic stem cell transplantation (HSCT) and hematological research. He earned his MD from the Medical University of Silesia in 1989, followed by a fellowship in 1990. Throughout his career, he has worked in prestigious institutions such as the Medical University of Silesia, Katowice, Poland, and the Albany Medical College in New York. Professor Markiewicz’s research has led to numerous high-impact publications, and he is known for his expertise in myelodysplastic syndrome (MDS), graft-versus-host disease (GVHD), and treatment outcomes in bone marrow transplantation. His commitment to research and clinical excellence has earned him recognition as a leader in his field.

Publication Profile: 

Orcid

Strengths for the Award:

Prof. Mirosław Markiewicz is a leading expert in the field of hematology, particularly in hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD), and myelodysplastic syndrome (MDS). His vast clinical experience and academic achievements, including over 114 publications with an impressive impact factor (IF 217.467) and a Hirsch Index of 12, demonstrate his dedication to advancing medical science. Prof. Markiewicz’s research contributions have been instrumental in improving patient outcomes in hematology, particularly in understanding conditioning regimens for HSCT, and exploring genetic and environmental factors in diseases like multiple myeloma. His leadership roles in various institutions and collaborative work with other prominent scientists further underscore his position as a top researcher in his field.

Areas for Improvements:

While Prof. Markiewicz has an extensive publication record, further engagement in multi-disciplinary research approaches could strengthen his contributions to immunotherapy and the intersection of hematology and precision medicine. Additionally, more involvement in international collaborative research projects could expand the global impact of his findings.

Education:

Mirosław Markiewicz completed his academic journey at renowned institutions, beginning with his MD degree from the Medical University of Silesia in 1989. He further enhanced his expertise through a fellowship in hematology in 1990. His early career was focused on internal medicine and hematology, which laid the foundation for his future work in hematopoietic stem cell transplantation. In 2008, he achieved habilitation, the Polish equivalent of a postdoctoral qualification, and in 2015, he attained professorship status. Over the years, Professor Markiewicz has continued to enrich his academic portfolio with numerous research accomplishments. He has worked at several leading medical institutions, including the Medical University of Silesia, Katowice, and the Department of Hematology at the University of Masku. His educational journey reflects an unwavering commitment to advancing knowledge in hematology and improving patient care through clinical and laboratory research.

Experience:

Professor Mirosław Markiewicz boasts an extensive career in hematology and bone marrow transplantation. From 1992 to 2001, he served as an Assistant Professor at the Medical University of Silesia, where he began his work in the Department of Hematology and Bone Marrow Transplantation. He subsequently became the Head of the Department of Hematology at the same institution, a role he held from 2001 to 2017. During this period, he contributed to expanding the scope of hematological care and research in Poland. Between 2017 and 2019, Professor Markiewicz held a prominent position as Head of the Department at the Department of Hematology at Rzeszów University. In 2019, he joined the University of Ransomw, continuing his research and clinical leadership in hematology. His vast clinical experience spans diagnosis, treatment, and transplantation, particularly focusing on myelodysplastic syndrome and acute leukemia, among other complex hematological disorders.

Research Focus:

Professor Mirosław Markiewicz’s research primarily revolves around hematopoietic stem cell transplantation (HSCT), bone marrow transplantation (BMT), and the management of hematological malignancies. His work focuses on the clinical outcomes of hematopoietic stem cell transplantation in patients with myelodysplastic syndrome (MDS), acute leukemia, and other hematologic disorders. Additionally, his research explores graft-versus-host disease (GVHD), a common complication following allogeneic stem cell transplantation, and strategies for its prevention and management. One of his primary areas of interest is the use of novel conditioning regimens, such as treosulfan-based conditioning, and their comparison with traditional therapies in improving patient outcomes. Furthermore, Professor Markiewicz has contributed to studies on the genetic predisposition to hematological cancers and the molecular mechanisms of disease progression. His publications, covering clinical trials, transplant outcomes, and immunological factors, have had a significant impact on the field of hematology and transplantation.

Publications Top Notes:

  1. “Alogeneic hematopoietic stem cell transplantation with CD14-selected CITT cells add-back in high-risk patients” 🧬💉
  2. “Hematopoietic stem cell transplantation with minor biocompatibility antigen disparities” ⚖️🧬
  3. “Treating rapid development of unclassified myeloid lineage acute leukaemia with trisomy 6 and U2AF1 mutation” 🔬⚡
  4. “Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS” 📊🔬
  5. “The role of lifestyle and environmental factors in the pathogenesis of multiple myeloma” 🌱🧬
  6. “Fludarabine-treosulfan versus fludarabine-melphalan conditioning in older AML patients” 🧪💉
  7. “Polymorphisms within autophagy-related genes as susceptibility biomarkers for multiple myeloma” 🧬📚
  8. “Graft-versus-host disease and survival in patients with MDS after treosulfan- versus busulfan-based conditioning” 🔬🧬
  9. “Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation” 🧪🧬
  10. “Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes” 💉⚖️

Conclusion:

Prof. Mirosław Markiewicz’s work represents the cutting edge of hematology research, particularly in stem cell transplantation and the treatment of hematologic malignancies. His academic rigor, innovative research, and clinical expertise make him a deserving candidate for the Research for Best Researcher Award.